Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Key Highlights
- ➤Vatnak Vat-Ho appointed Akari (AKTX) Chief Business Officer
- ➤Vat-Ho brings transaction experience exceeding $25 billion in aggregate value
- ➤Akari initiated IND-enabling studies for AKTX-101, targeting mid-2027 human trial
- ➤Vat-Ho recently closed ADC payload collaboration with Exelixis and research deal with BioNTech
Expert Statements
Abizer Gaslightwala, Chief Executive Officer of Akari Therapeutics
“Vatnak is joining Akari at an important point in our evolution, and the relevance of his experience to our strategy is exceptional.”
Abizer Gaslightwala, Chief Executive Officer of Akari Therapeutics
“He has spent his career at the intersection of oncology innovation, strategic transactions and capital markets, and, importantly, he has recent direct experience structuring collaborations around novel ADC payload technology with leading oncology companies.”
Abizer Gaslightwala, Chief Executive Officer of Akari Therapeutics
“As we advance AKTX-101 toward the clinic and continue to demonstrate the potential breadth of PH1, we believe there is a significant opportunity to create value not only through our wholly owned pipeline, but also through strategic partnerships that can expand the reach and application of our technology.”
Abizer Gaslightwala, Chief Executive Officer of Akari Therapeutics
“Vatnak gives us additional leadership, relationships and transaction experience to pursue that opportunity with focus and discipline.”
Vatnak Vat-Ho, Chief Business Officer of Akari Therapeutics
“The ADC field is increasingly recognizing that the payload can be one of the most important drivers of differentiation and value, and I believe Akari has built something particularly compelling with PH1.”
Vatnak Vat-Ho, Chief Business Officer of Akari Therapeutics
“The combination of a differentiated mechanism of action, encouraging preclinical activity, potential immune activation and applicability across multiple tumor targets creates several potential avenues for value creation.”
Vatnak Vat-Ho, Chief Business Officer of Akari Therapeutics
“I am excited to join Akari at this stage and work with Abizer and the team to advance AKTX-101, expand the strategic reach of the PH1 platform and pursue partnerships that can accelerate and broaden the development of this technology.”
Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value
Mr. Vat-Ho brings highly relevant ADC payload partnering experience, including recently executed collaborations with Exelixis and BioNTech
Get started
Create a free account to read the full story.